Clinical trial
A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment
NCT06215755 is registered in ClinicalTrials.gov with Verge Genomics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment
- Lead sponsor
- Verge Genomics
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 15, 2024
- Completion date
- July 7, 2025
- Enrollment
- 54 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.